{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:34:07Z","timestamp":1768538047955,"version":"3.49.0"},"reference-count":89,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2016-0042_s_999_w2aab3b8c27b1b7b1aab1c14b1Aa\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Serum concentrations of estradiol (E\n                      <jats:sub>2<\/jats:sub>\n                      ) and testosterone (testo) measured by mass spectrometry-based assays should remain below the 95th centile measured at 9.3 pg\/mL for E\n                      <jats:sub>2<\/jats:sub>\n                      and 0.26 ng\/mL for testo in normal postmenopausal women in order to avoid the risk of non-physiological systemic exposure to elevated serum concentrations of these two sex steroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2016-0042_s_998_w2aab3b8c27b1b7b1aab1c14b2Aa\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Serum E\n                      <jats:sub>2<\/jats:sub>\n                      and testo, as well as dehydroepiandrosterone (DHEA) and nine of its other metabolites, were measured at 10 time intervals over 24 h on the first and seventh days of daily intravaginal administration of 0.50% (6.5 mg) DHEA by validated mass spectrometry-based assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2016-0042_s_997_w2aab3b8c27b1b7b1aab1c14b3Aa\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      No biologically significant change in the individual serum concentrations of E\n                      <jats:sub>2<\/jats:sub>\n                      , testo or DHEA was observed. Most importantly, estrone sulfate (E\n                      <jats:sub>1<\/jats:sub>\n                      -S) and the glucuronidated androgen metabolites also remained within normal values, thus confirming the absence of biologically significant systemic exposure in line with intracrinology. Using data from the literature, comparison is made with serum E\n                      <jats:sub>2<\/jats:sub>\n                      above normal postmenopausal values following administration of 10-\u03bcg E\n                      <jats:sub>2<\/jats:sub>\n                      tablets.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2016-0042_s_996_w2aab3b8c27b1b7b1aab1c14b4Aa\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While the clinical program on vulvovaginal atrophy has shown the efficacy and safety of intravaginal 6.5 mg of DHEA (prasterone), the present data illustrate in detail the serum levels of the individual sex steroids and their metabolites derived from DHEA. The data obtained are in line with the physiology of intracrinology and confirm an action limited to the vagina as the serum concentrations of all sex steroids are maintained within the normal values of menopause, thus protecting the uterus and most likely other tissues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2016-0042","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T05:01:35Z","timestamp":1482210095000},"page":"39-60","source":"Crossref","is-referenced-by-count":11,"title":["A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values"],"prefix":"10.1515","volume":"29","author":[{"given":"Fernand","family":"Labrie","sequence":"first","affiliation":[{"name":"Endoceutics Inc., 2795 Laurier Blvd, Suite 500, Quebec City, Quebec, G1V 4M7, Canada , Phone: +(418) 653-0055, Fax: +(418) 653-3635"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Martel","sequence":"additional","affiliation":[{"name":"Endoceutics Inc., Quebec City, Quebec, G1V 4M7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"key":"2025121207215687487_j_hmbci-2016-0042_ref_001_w2aab3b8c27b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011;18:30\u201343.","DOI":"10.1097\/gme.0b013e3181e195a6"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_002_w2aab3b8c27b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, B\u00e9langer A, B\u00e9langer P, B\u00e9rub\u00e9 R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182\u20138.","DOI":"10.1016\/j.jsbmb.2006.02.004"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_003_w2aab3b8c27b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Martel C, B\u00e9rub\u00e9 R, Cote I, Labrie C, Cusan L, Gomez JL. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359\u201367.","DOI":"10.1016\/j.jsbmb.2013.08.002"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_004_w2aab3b8c27b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 2013;16:205\u201313.","DOI":"10.3109\/13697137.2012.733983"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_005_w2aab3b8c27b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113\u20138.","DOI":"10.1016\/0303-7207(91)90116-A"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_006_w2aab3b8c27b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Luu-The V, B\u00e9langer A, Lin SX, Simard J, Labrie C. Is DHEA a hormone? Starling Review. J Endocrinol 2005;187:169\u201396.","DOI":"10.1677\/joe.1.06264"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_007_w2aab3b8c27b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Labrie C, B\u00e9langer A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412\u20137.","DOI":"10.1210\/endo-123-3-1412"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_008_w2aab3b8c27b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Labrie F. Androgens in postmenopausal women: their practically exclusive intracrine formation and inactivation in peripheral tissues. In: Plouffe L, Rizk B, editors. Androgens in Gynecological Practice: Published by Cambridge University Press, 2015:64\u201373.","DOI":"10.1017\/CBO9781139649520.008"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_009_w2aab3b8c27b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"B\u00e9langer A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003;14:473\u20139.","DOI":"10.1016\/j.tem.2003.10.005"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_010_w2aab3b8c27b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"B\u00e9langer B, B\u00e9langer A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695\u20138.","DOI":"10.1016\/0022-4731(89)90514-1"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_011_w2aab3b8c27b1b7b1ab2b1c11Aa","unstructured":"Labrie F. DHEA after Menopause \u2013 Sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 2010;19:14\u201324."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_012_w2aab3b8c27b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Labrie F. DHEA, important source of sex steroids in men and even more in women. In: Martini L, Chrousos G. P, Labrie F, Pacak K, Pfaff D, editors. Neuroendocrinology, the normal neuroendocrine system, progress in brain research. Amsterdam, The Netherlands: Elsevier, 2010;182 (Chapter 4):97\u2013148.","DOI":"10.1016\/S0079-6123(10)82004-7"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_013_w2aab3b8c27b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol 2015;145:133\u20138.","DOI":"10.1016\/j.jsbmb.2014.06.001"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_014_w2aab3b8c27b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, B\u00e9langer A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396\u2013402.","DOI":"10.1210\/jcem.82.8.4160"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_015_w2aab3b8c27b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Labrie F. Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007;3:584\u201393.","DOI":"10.1038\/ncpendmet0559"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_016_w2aab3b8c27b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Rainey WE, Parker CR, Jr., Rehman K, Carr BR. The adrenal genetic puzzle: how do the fetal and adult pieces differ? Endocr Res 2002;28:611\u201322.","DOI":"10.1081\/ERC-120016974"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_017_w2aab3b8c27b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, C\u00f4t\u00e9 I, Lavoie L, Martel C, Balser J, other participating members of the VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (prasterone). Menopause 2015;22:950\u201363.","DOI":"10.1097\/GME.0000000000000428"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_018_w2aab3b8c27b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dub\u00e9 R, C\u00f4t\u00e9 I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone) a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907\u201322.","DOI":"10.1097\/gme.0b013e31819e8e2d"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_019_w2aab3b8c27b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dub\u00e9 R, C\u00f4t\u00e9 I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282\u20138.","DOI":"10.3109\/13697137.2010.535226"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_020_w2aab3b8c27b1b7b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E, members of the VVAPRG. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243\u201356.","DOI":"10.1097\/GME.0000000000000571"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_021_w2aab3b8c27b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dub\u00e9 R, C\u00f4t\u00e9 I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923\u201331.","DOI":"10.1097\/gme.0b013e31819e85c6"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_022_w2aab3b8c27b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (Dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med 2014;11:1766\u201385.","DOI":"10.1111\/jsm.12517"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_023_w2aab3b8c27b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E, Members of the VVAPRG. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. J Sex Med 2015;12:2401\u201312.","DOI":"10.1111\/jsm.13045"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_024_w2aab3b8c27b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Cote I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the VVAPG. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig 2016;25:181\u201390.","DOI":"10.1515\/hmbci-2015-0044"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_025_w2aab3b8c27b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Cusan L, Gomez JL, Cote I, Berube R, Belanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178\u201394.","DOI":"10.1016\/j.jsbmb.2008.06.003"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_026_w2aab3b8c27b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Cusan L, Gomez JL, C\u00f4t\u00e9 I, B\u00e9rub\u00e9 R, B\u00e9langer P, Martel C, Labrie C. Corrigendum to: Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;112:169.","DOI":"10.1016\/j.jsbmb.2008.09.007"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_027_w2aab3b8c27b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dub\u00e9 R, C\u00f4t\u00e9 I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897\u2013906.","DOI":"10.1097\/gme.0b013e31819e8930"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_028_w2aab3b8c27b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Ke Y, Gonthier R, Simard JN, Archer D, Lavoie L, Martel C, Vaillancourt M, Labrie F. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA. Horm Mol Biol Clin Investig 2015;24:117\u201329.","DOI":"10.1515\/hmbci-2015-0035"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_029_w2aab3b8c27b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research G. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. J Steroid Biochem Mol Biol 2015;154:186\u201396.","DOI":"10.1016\/j.jsbmb.2015.08.016"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_030_w2aab3b8c27b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur E. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol 2016;159:142\u201353.","DOI":"10.1016\/j.jsbmb.2016.03.016"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_031_w2aab3b8c27b1b7b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency\u2013a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121\u20137.","DOI":"10.1016\/0378-5122(92)90246-Z"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_032_w2aab3b8c27b1b7b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17 beta-estradiol vaginal tablets. Climacteric 2010;13:219\u201327.","DOI":"10.3109\/13697137.2010.483297"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_033_w2aab3b8c27b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556\u201362.","DOI":"10.1097\/00006250-200204000-00008"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_034_w2aab3b8c27b1b7b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Holmberg L, Iversen OE, Rudenstam CM, Hammar M, E. K, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, Group. HS. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475\u201382.","DOI":"10.1093\/jnci\/djn058"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_035_w2aab3b8c27b1b7b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Pickar JH, Amadio JM, Bernick BA, Mirkin S. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. Climacteric 2016;19:181\u20137.","DOI":"10.3109\/13697137.2015.1136926"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_036_w2aab3b8c27b1b7b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Cusan L, Gomez JL, Martel C, B\u00e9rub\u00e9 R, B\u00e9langer P, B\u00e9langer A, Vandenput L, Mellstr\u00f6m D, Ohlsson C. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52\u20136.","DOI":"10.1016\/j.jsbmb.2008.11.004"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_037_w2aab3b8c27b1b7b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, Cusan L, Gomez JL, Cote I, Berube R, Belanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30\u20136.","DOI":"10.1097\/gme.0b013e31817b6132"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_038_w2aab3b8c27b1b7b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Labrie F, B\u00e9langer A, Labrie C, Candas B, Cusan L, Gomez JL. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. J Steroid Biochem Mol Biol 2007;107:57\u201369.","DOI":"10.1016\/j.jsbmb.2007.02.007"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_039_w2aab3b8c27b1b7b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Luu-The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC, Labrie F. Full length cDNA structure and deduced amino acid sequence of human 3b-hydroxy-5-ene steroid dehydrogenase. Mol Endocrinol 1989;3:1310\u20132.","DOI":"10.1210\/mend-3-8-1310"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_040_w2aab3b8c27b1b7b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047\u201359.","DOI":"10.1016\/S0140-6736(97)08233-0"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_041_w2aab3b8c27b1b7b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321\u201333.","DOI":"10.1001\/jama.288.3.321"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_042_w2aab3b8c27b1b7b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354\u201360.","DOI":"10.1097\/01.AOG.0000241091.86268.6e"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_043_w2aab3b8c27b1b7b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino L. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 2008;19:150\u20135.","DOI":"10.1093\/annonc\/mdm404"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_044_w2aab3b8c27b1b7b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Li L, Plummer SJ, Thompson CL, Merkulova A, Acheson LS, Tucker TC, Casey G. A common 8q24 variant and the risk of colon cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:339\u201342.","DOI":"10.1158\/1055-9965.EPI-07-0713"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_045_w2aab3b8c27b1b7b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419\u201327.","DOI":"10.1016\/S0140-6736(03)14065-2"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_046_w2aab3b8c27b1b7b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497\u2013504.","DOI":"10.1093\/jnci\/94.7.497"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_047_w2aab3b8c27b1b7b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc 2001;285:1460\u20135.","DOI":"10.1001\/jama.285.11.1460"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_048_w2aab3b8c27b1b7b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304\u201313.","DOI":"10.1016\/0029-7844(94)00383-O"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_049_w2aab3b8c27b1b7b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543\u201351.","DOI":"10.1016\/S0140-6736(05)66455-0"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_050_w2aab3b8c27b1b7b1ab2b1c50Aa","unstructured":"Archer DF. Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data. J Reprod Med 2007;52(2 Suppl):159\u201364."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_051_w2aab3b8c27b1b7b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156\u201361.","DOI":"10.1097\/00042192-200007030-00005"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_052_w2aab3b8c27b1b7b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001;27:255\u201360.","DOI":"10.1111\/j.1447-0756.2001.tb01266.x"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_053_w2aab3b8c27b1b7b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 2005;41:2673\u201381.","DOI":"10.1016\/j.ejca.2005.07.015"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_054_w2aab3b8c27b1b7b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O\u2019Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83\u201392.","DOI":"10.1080\/13697130500087016"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_055_w2aab3b8c27b1b7b1ab2b1c55Aa","unstructured":"Galhardo CL, Soares JM, Jr., Simoes RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol 2006;33:85\u20139."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_056_w2aab3b8c27b1b7b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584\u20137.","DOI":"10.1093\/annonc\/mdj127"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_057_w2aab3b8c27b1b7b1ab2b1c57Aa","doi-asserted-by":"crossref","unstructured":"Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737\u201343.","DOI":"10.1097\/01.gme.0000227401.98933.0b"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_058_w2aab3b8c27b1b7b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67\u201376.","DOI":"10.1097\/01.AOG.0000296714.12226.0f"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_059_w2aab3b8c27b1b7b1ab2b1c59Aa","doi-asserted-by":"crossref","unstructured":"Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.","DOI":"10.1186\/bcr1378"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_060_w2aab3b8c27b1b7b1ab2b1c60Aa","doi-asserted-by":"crossref","unstructured":"Gallagher JC, Riggs BL. Current concepts in nutrition. Nutrition and bone disease. N Engl J Med 1978;298:193\u20135.","DOI":"10.1056\/NEJM197801262980405"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_061_w2aab3b8c27b1b7b1ab2b1c61Aa","doi-asserted-by":"crossref","unstructured":"Martin PL, Yen SS, Burnier AM, Hermann H. Systemic absorption and sustained effects of vaginal estrogen creams. J Am Med Assoc 1979;242:2699\u2013700.","DOI":"10.1001\/jama.1979.03300240039024"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_062_w2aab3b8c27b1b7b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"Furuhjelm M, Karlgren E, Carlstrom K. Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int J Gynaecol Obstet 1980;17:335\u20139.","DOI":"10.1002\/j.1879-3479.1980.tb00295.x"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_063_w2aab3b8c27b1b7b1ab2b1c63Aa","doi-asserted-by":"crossref","unstructured":"Deutsch S, Ossowski R, Benjamin I. Comparison between degree of systemic absorption of vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am J Obstet Gynecol 1981;139:967\u20138.","DOI":"10.1016\/0002-9378(81)90972-8"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_064_w2aab3b8c27b1b7b1ab2b1c64Aa","doi-asserted-by":"crossref","unstructured":"Mandel FP, Geola FL, Meldrum DR, Lu JH, Eggena P, Sambhi MP, Hershman JM, Judd HL. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133\u20139.","DOI":"10.1210\/jcem-57-1-133"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_065_w2aab3b8c27b1b7b1ab2b1c65Aa","unstructured":"Martin PL, Greaney MO, Burnier AM, Brooks PM, Yen SS, Quigley ME. Estradiol, estrone, and gonadotropin levels after use of vaginal estradiol. Obstet Gynecol 1984;63:441\u20134."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_066_w2aab3b8c27b1b7b1ab2b1c66Aa","unstructured":"Whitehead MI, Minardi J, Kitchin Y. Sharpless. Systemic absorption of estrogen from Premarin vaginal cream. In: Cooke ID, ed. The role of estrogen\/progestagen in the management of menopause. Lancaster: MTP Press, 1986:63\u201370."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_067_w2aab3b8c27b1b7b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"Mattson LA, Culberg G, Eriksson O, Kruitsson F. Vaginal administration of low dose estradiol-effects on endometrium and vaginal cytology. Maturitas 1989;11:217\u201322.","DOI":"10.1016\/0378-5122(89)90213-2"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_068_w2aab3b8c27b1b7b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991;14:23\u201331.","DOI":"10.1016\/0378-5122(91)90144-F"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_069_w2aab3b8c27b1b7b1ab2b1c69Aa","unstructured":"US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2013 Prescribing Information for Health Care Providers and Patient Labeling. Center for Drug Evaluation and Research (CDER) February 2004, Revision 1. 2004. Available at: http:\/\/wwwfdagov\/cder\/guidance\/5670dftpdf."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_070_w2aab3b8c27b1b7b1ab2b1c70Aa","doi-asserted-by":"crossref","unstructured":"Birkhauser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108\u201323.","DOI":"10.1080\/13697130801983921"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_071_w2aab3b8c27b1b7b1ab2b1c71Aa","doi-asserted-by":"crossref","unstructured":"NAMS: The North American Menopause Society. Estrogen and progestogen use in postemenopausal women. Menopause 2008;5:584\u2013602.","DOI":"10.1097\/gme.0b013e31817b076a"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_072_w2aab3b8c27b1b7b1ab2b1c72Aa","doi-asserted-by":"crossref","unstructured":"Holmgren PA, Lindskog M, von Schoultz B. Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas 1989;11:55\u201363.","DOI":"10.1016\/0378-5122(89)90120-5"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_073_w2aab3b8c27b1b7b1ab2b1c73Aa","doi-asserted-by":"crossref","unstructured":"Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261\u201371.","DOI":"10.1200\/JCO.2004.08.029"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_074_w2aab3b8c27b1b7b1ab2b1c74Aa","doi-asserted-by":"crossref","unstructured":"Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, Carbonez A, Van Huffel S, Ameye L, Paridaens R. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753\u201360.","DOI":"10.1097\/00001813-200409000-00003"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_075_w2aab3b8c27b1b7b1ab2b1c75Aa","unstructured":"Kvorning I, Daugbjerg NU, Jensen HK, Saurbrey N, Fink B, editors. Pharmaceutical development of lose-dose estradiol vagitories. The urogenital oestrogen deficiency syndrome: Proceedings of International Workshop. Copenhagen, 1986: 51\u201360."},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_076_w2aab3b8c27b1b7b1ab2b1c76Aa","doi-asserted-by":"crossref","unstructured":"Schiff I, Tulchinsky D, Ryan KJ. Vaginal absorption of estrone and 17beta-estradiol. Fertil Steril 1977;28:1063\u20136.","DOI":"10.1016\/S0015-0282(16)42855-4"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_077_w2aab3b8c27b1b7b1ab2b1c77Aa","doi-asserted-by":"crossref","unstructured":"Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228\u201337.","DOI":"10.3109\/13697137.2010.481058"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_078_w2aab3b8c27b1b7b1ab2b1c78Aa","doi-asserted-by":"crossref","unstructured":"Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;(22 Suppl):S43\u20137.","DOI":"10.1016\/0378-5122(95)00963-9"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_079_w2aab3b8c27b1b7b1ab2b1c79Aa","doi-asserted-by":"crossref","unstructured":"Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertungealp J, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, Stevenson JC. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004\/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8\u201314.","DOI":"10.1016\/j.maturitas.2005.02.019"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_080_w2aab3b8c27b1b7b1ab2b1c80Aa","doi-asserted-by":"crossref","unstructured":"Salminen HS, Saaf ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas 2007;57:370\u201381.","DOI":"10.1016\/j.maturitas.2007.03.005"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_081_w2aab3b8c27b1b7b1ab2b1c81Aa","doi-asserted-by":"crossref","unstructured":"Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 1997;177:115\u20139.","DOI":"10.1016\/S0002-9378(97)70448-4"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_082_w2aab3b8c27b1b7b1ab2b1c82Aa","doi-asserted-by":"crossref","unstructured":"Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001;86:2757\u201362.","DOI":"10.1210\/jc.86.6.2757"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_083_w2aab3b8c27b1b7b1ab2b1c83Aa","doi-asserted-by":"crossref","unstructured":"Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S. Superiority of gas chromatography\/tandem mass spectrometry assay (GC\/MS\/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007;72:666\u201371.","DOI":"10.1016\/j.steroids.2007.05.003"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_084_w2aab3b8c27b1b7b1ab2b1c84Aa","doi-asserted-by":"crossref","unstructured":"NAMS: The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 Position Statement of the North American Menopause Society,. Menopause 2007;14:357\u201369.","DOI":"10.1097\/gme.0b013e31805170eb"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_085_w2aab3b8c27b1b7b1ab2b1c85Aa","doi-asserted-by":"crossref","unstructured":"Baxendale PM, Reed MJ, James VH. Inability of human endometrium or myometrium to aromatize androstenedione. J Steroid Biochem 1981;14:305\u20136.","DOI":"10.1016\/0022-4731(81)90140-0"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_086_w2aab3b8c27b1b7b1ab2b1c86Aa","doi-asserted-by":"crossref","unstructured":"Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, Deb S. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359\u201383.","DOI":"10.1124\/pr.57.3.6"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_087_w2aab3b8c27b1b7b1ab2b1c87Aa","doi-asserted-by":"crossref","unstructured":"Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dube R, other participating members of the VVAPG. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 2015;22:1289\u201395.","DOI":"10.1097\/GME.0000000000000470"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_088_w2aab3b8c27b1b7b1ab2b1c88Aa","doi-asserted-by":"crossref","unstructured":"Ke Y, Bertin J, Gonthier R, Simard JN, Labrie F. A sensitive, simple and robust LC-MS\/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum. J Steroid Biochem Mol Biol 2014;144:523\u201334.","DOI":"10.1016\/j.jsbmb.2014.08.015"},{"key":"2025121207215687487_j_hmbci-2016-0042_ref_089_w2aab3b8c27b1b7b1ab2b1c89Aa","doi-asserted-by":"crossref","unstructured":"Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18:121\u201334.","DOI":"10.3109\/13697137.2014.947254"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2017.29.issue-2\/hmbci-2016-0042\/hmbci-2016-0042.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0042\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0042\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:16:11Z","timestamp":1765527371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0042\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,20]]},"references-count":89,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,12,20]]},"published-print":{"date-parts":[[2017,2,1]]}},"alternative-id":["10.1515\/hmbci-2016-0042"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2016-0042","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12,20]]}}}